103 related articles for article (PubMed ID: 24090904)
1. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Trechot P; Schmutz JL
Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
[No Abstract] [Full Text] [Related]
2. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.
Hsu CK; Hsu CC; Lee JY; Kuo YM; Pai MC
J Am Acad Dermatol; 2013 Feb; 68(2):e46-8. PubMed ID: 23317986
[No Abstract] [Full Text] [Related]
3. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
Hopkins CR
ACS Chem Neurosci; 2010 Aug; 1(8):533-4. PubMed ID: 22778845
[TBL] [Abstract][Full Text] [Related]
4. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
Cummings J
Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
[No Abstract] [Full Text] [Related]
5. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Schor NF
Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
[TBL] [Abstract][Full Text] [Related]
6. Lessons from a failed γ-secretase Alzheimer trial.
De Strooper B
Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
[TBL] [Abstract][Full Text] [Related]
7. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
8. Molecule of the month. Semagacestat.
Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
[No Abstract] [Full Text] [Related]
9. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.
Henley DB; Sundell KL; Sethuraman G; Dowsett SA; May PC
Curr Med Res Opin; 2014 Oct; 30(10):2021-32. PubMed ID: 24983746
[TBL] [Abstract][Full Text] [Related]
10. New pathway links γ-secretase to inflammation and memory while sparing notch.
Gandy S; Wustman B
Ann Neurol; 2011 Jan; 69(1):5-7. PubMed ID: 21280069
[No Abstract] [Full Text] [Related]
11. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
Samson K
Ann Neurol; 2010 Oct; 68(4):A9-A12. PubMed ID: 20976761
[No Abstract] [Full Text] [Related]
12. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Imbimbo BP; Peretto I
Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
[TBL] [Abstract][Full Text] [Related]
13. Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase.
O'Sullivan Coyne G; Woodring TS; Lee CR; Chen AP; Kong HH
J Invest Dermatol; 2018 Apr; 138(4):979-981. PubMed ID: 29138057
[No Abstract] [Full Text] [Related]
14. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
15. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
De Strooper B; Chávez Gutiérrez L
Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
[TBL] [Abstract][Full Text] [Related]
16. [The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].
Masuda S
Rinsho Ketsueki; 2006 Jul; 47(7):557-63. PubMed ID: 16910563
[No Abstract] [Full Text] [Related]
17. [Gamma-secretase inhibitors and modulators].
Iwai A
Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():83-7. PubMed ID: 22755160
[No Abstract] [Full Text] [Related]
18. Alzheimer's failure raises questions about disease-modifying strategies.
Extance A
Nat Rev Drug Discov; 2010 Oct; 9(10):749-51. PubMed ID: 20885394
[No Abstract] [Full Text] [Related]
19. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
20. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
